[Newsmp] While the Seoul Central District Court ruling involving Medytox and Daewoong Pharmaceutical came out, Evolus, the global distributor of Daewoong’s Nabota, officially announced that the civil judgment of the Seoul Central District Court does not affect the production, export, or overseas sales of Jeaveau (American name) or Neceiva (European name).
Evolus earlier reached an agreement with Medytox in February 2021, stipulating the continued manufacturing and commercialization of Nabota regardless of the outcome of the Korean lawsuit between Daewoong Pharmaceutical and Medytox.
According to the settlement, Daewoong Pharmaceutical has the right to manufacture and export Nabota to Evolsus, and Evolsus is granted to continue commercializing the product.
“We will apply for suspension of execution and appeal immediately to ensure that there are no problems with the production and sales of Nabota while correcting the clear misjudgment of the court decision,” Daewoong official said. “Daewoong will continue to promote K-Bio’s technology to the world through Korea’s representative botulinum toxin Nabota, which has proven its own technology and best quality.”
